M.A. KUNST^1, 2, Z.M. KADYROVA², А.V. KOSTERINA², YA.A. HADJ¹, L.K. BOMBINA^1, 2

 ¹Republic Clinical Hospital, Kazan

²Kazan State Medical University, Kazan

  Contact details:

Kosterina A.V. ― Assistant Lecturer of the Department of Hospital Therapy

Address: 49 Butlerov St., Kazan, Russian Federation, 420012, tel.: +7-917-273-77-68, e-mail: avakost@mail.ru

 Great progress has been achieved in the treatment of oncological diseases; however, the problem of the occurrence of secondary malignant neoplasms remains actual, among which hematologic malignancies are common. The development of secondary tumors is of particular interest, because the individual predisposition of the body to malignant transformation of cells and the carcinogenic effect of antitumor therapy of primary cancer are possible etiological factors. The article presents a review of literature devoted to the cases of secondary malignant neoplasms that emerged after antitumor treatment. A clinical case of a secondary myelodysplastic syndrome developed after chemotherapy in the treatment of primary acute lymphoblastic leukemia is described.

Key words: secondary malignant neoplasms, acute lymphoblastic leukemia, myelodysplastic syndrome.

REFERENCES

1. Nottage K., Lanctot J., Li Z. et al. Long-term risk for subsequent leukemia after treatment for childhood cancer: a report from the Childhood Cancer Survivor Study. Blood, 2011, vol. 117 (23), pp. 6315–6318.
2. Turcotte L.M., Liu Q., Yasui Y. et al. Temporal Trends in Treatment and Subsequent Neoplasm Risk Among 5-Year Survivors of Childhood Cancer, 1970–2015. JAMA, 2017, vol. 317 (8), pp. 814–824.
3. Rihani R., Bazzeh F., Faqih N. et al. Secondary hematopoietic malignancies in survivors of childhood cancer: an analysis of 111 cases from the Surveillance, Epidemiology, and End Result-9 registry. Cancer, 2010, vol. 116 (18), pp. 4385–4394.
4. Grosse Y., Baan R., Straif K. et al. A review of human carcinogens — Part A: pharmaceuticals. Lancet Oncol, 2009, no. 1, pp. 13–14.
5. Solenova L.G. Second primary tumors in cancer patients: epidemiology, the role of anticancer therapy. Uspekhi molekulyarnoy onkologii, 2016, vol. 3, pp. 30–43.
6. Pedersen-Bjergaard J., Pedersen M., Roulston D. et al. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood, 1995, vol. 86 (9), pp. 3542–3552.
7. Domracheva E.V., Aseeva E.A., Neverova A.L et al. Leukemias and myelodysplastic syndromes that arose after antitumor therapy: results of 16-year observations. Klinicheskaya onkogematologiya, 2011, vol. 4, no. 2, pp. 120–133.
8. Larson R.A. Etiology and management of therapy-related myeloid leukemia. Hematology Am Soc Hematol Educ Program, 2007, vol. 2007 (1), pp. 453–459.